Financhill
Sell
39

LMAT Quote, Financials, Valuation and Earnings

Last price:
$81.83
Seasonality move :
12.95%
Day range:
$79.15 - $82.29
52-week range:
$62.39 - $109.58
Dividend yield:
0.83%
P/E ratio:
42.22x
P/S ratio:
8.48x
P/B ratio:
5.48x
Volume:
157.8K
Avg. volume:
235K
1-year change:
21.35%
Market cap:
$1.8B
Revenue:
$219.9M
EPS (TTM):
$1.94

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LMAT
LeMaitre Vascular
$56M $0.49 7.74% 13.38% $105.63
BDX
Becton Dickinson &
$5.5B $3.56 6.03% 77.19% $276.77
BSX
Boston Scientific
$4.8B $0.71 18.49% 103.33% $115.62
GMED
Globus Medical
$646.2M $0.75 6.09% 580.52% $98.69
MMSI
Merit Medical Systems
$351.5M $0.83 8.97% 56.02% $118.20
PODD
Insulet
$582M $1.02 23.07% 6.17% $314.06
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LMAT
LeMaitre Vascular
$81.91 $105.63 $1.8B 42.22x $0.20 0.83% 8.48x
BDX
Becton Dickinson &
$225.98 $276.77 $64.9B 37.54x $1.04 1.76% 3.18x
BSX
Boston Scientific
$97.16 $115.62 $143.4B 77.73x $0.00 0% 8.62x
GMED
Globus Medical
$71.04 $98.69 $9.8B 94.72x $0.00 0% 3.88x
MMSI
Merit Medical Systems
$98.94 $118.20 $5.8B 48.74x $0.00 0% 4.33x
PODD
Insulet
$255.44 $314.06 $17.9B 44.12x $0.00 0% 9.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LMAT
LeMaitre Vascular
33.22% 2.713 8.07% 10.77x
BDX
Becton Dickinson &
42.67% 0.476 28.8% 0.44x
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
GMED
Globus Medical
9.6% 2.915 3.9% 1.72x
MMSI
Merit Medical Systems
34.59% 1.540 12.84% 2.71x
PODD
Insulet
53.47% 1.510 7.6% 2.50x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LMAT
LeMaitre Vascular
$38.6M $12.9M 12.5% 13.81% 31.73% $13.1M
BDX
Becton Dickinson &
$2.2B $546M 3.92% 6.75% 8.92% $588M
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
GMED
Globus Medical
$393.9M $77.1M 2.31% 2.56% 11.72% $193.2M
MMSI
Merit Medical Systems
$173M $36.7M 5.83% 9.36% 11.58% $64.5M
PODD
Insulet
$430.9M $109.3M 17.64% 43.11% 20.08% $91.7M

LeMaitre Vascular vs. Competitors

  • Which has Higher Returns LMAT or BDX?

    Becton Dickinson & has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 5.86%. LeMaitre Vascular's return on equity of 13.81% beat Becton Dickinson &'s return on equity of 6.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.26% $0.49 $505.1M
    BDX
    Becton Dickinson &
    43.25% $1.04 $44B
  • What do Analysts Say About LMAT or BDX?

    LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Becton Dickinson & has an analysts' consensus of $276.77 which suggests that it could grow by 22.48%. Given that LeMaitre Vascular has higher upside potential than Becton Dickinson &, analysts believe LeMaitre Vascular is more attractive than Becton Dickinson &.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    BDX
    Becton Dickinson &
    8 3 0
  • Is LMAT or BDX More Risky?

    LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.526%.

  • Which is a Better Dividend Stock LMAT or BDX?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Becton Dickinson & offers a yield of 1.76% to investors and pays a quarterly dividend of $1.04 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or BDX?

    LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. LeMaitre Vascular's net income of $11.2M is lower than Becton Dickinson &'s net income of $303M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Becton Dickinson &'s PE ratio is 37.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 3.18x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.48x 42.22x $55.7M $11.2M
    BDX
    Becton Dickinson &
    3.18x 37.54x $5.2B $303M
  • Which has Higher Returns LMAT or BSX?

    Boston Scientific has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 12.41%. LeMaitre Vascular's return on equity of 13.81% beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.26% $0.49 $505.1M
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
  • What do Analysts Say About LMAT or BSX?

    LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19%. Given that LeMaitre Vascular has higher upside potential than Boston Scientific, analysts believe LeMaitre Vascular is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    BSX
    Boston Scientific
    23 4 0
  • Is LMAT or BSX More Risky?

    LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

  • Which is a Better Dividend Stock LMAT or BSX?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or BSX?

    LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Boston Scientific quarterly revenues of $4.6B. LeMaitre Vascular's net income of $11.2M is lower than Boston Scientific's net income of $566M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Boston Scientific's PE ratio is 77.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 8.62x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.48x 42.22x $55.7M $11.2M
    BSX
    Boston Scientific
    8.62x 77.73x $4.6B $566M
  • Which has Higher Returns LMAT or GMED?

    Globus Medical has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 4.03%. LeMaitre Vascular's return on equity of 13.81% beat Globus Medical's return on equity of 2.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.26% $0.49 $505.1M
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
  • What do Analysts Say About LMAT or GMED?

    LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Globus Medical has an analysts' consensus of $98.69 which suggests that it could grow by 38.93%. Given that Globus Medical has higher upside potential than LeMaitre Vascular, analysts believe Globus Medical is more attractive than LeMaitre Vascular.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    GMED
    Globus Medical
    6 4 0
  • Is LMAT or GMED More Risky?

    LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.608%.

  • Which is a Better Dividend Stock LMAT or GMED?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or GMED?

    LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Globus Medical quarterly revenues of $657.3M. LeMaitre Vascular's net income of $11.2M is lower than Globus Medical's net income of $26.5M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Globus Medical's PE ratio is 94.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 3.88x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.48x 42.22x $55.7M $11.2M
    GMED
    Globus Medical
    3.88x 94.72x $657.3M $26.5M
  • Which has Higher Returns LMAT or MMSI?

    Merit Medical Systems has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 7.87%. LeMaitre Vascular's return on equity of 13.81% beat Merit Medical Systems's return on equity of 9.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.26% $0.49 $505.1M
    MMSI
    Merit Medical Systems
    48.71% $0.46 $2.1B
  • What do Analysts Say About LMAT or MMSI?

    LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 19.47%. Given that LeMaitre Vascular has higher upside potential than Merit Medical Systems, analysts believe LeMaitre Vascular is more attractive than Merit Medical Systems.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    MMSI
    Merit Medical Systems
    5 1 0
  • Is LMAT or MMSI More Risky?

    LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

  • Which is a Better Dividend Stock LMAT or MMSI?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or MMSI?

    LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Merit Medical Systems quarterly revenues of $355.2M. LeMaitre Vascular's net income of $11.2M is lower than Merit Medical Systems's net income of $27.9M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Merit Medical Systems's PE ratio is 48.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 4.33x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.48x 42.22x $55.7M $11.2M
    MMSI
    Merit Medical Systems
    4.33x 48.74x $355.2M $27.9M
  • Which has Higher Returns LMAT or PODD?

    Insulet has a net margin of 20.07% compared to LeMaitre Vascular's net margin of 16.85%. LeMaitre Vascular's return on equity of 13.81% beat Insulet's return on equity of 43.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    LMAT
    LeMaitre Vascular
    69.26% $0.49 $505.1M
    PODD
    Insulet
    72.12% $1.39 $2.6B
  • What do Analysts Say About LMAT or PODD?

    LeMaitre Vascular has a consensus price target of $105.63, signalling upside risk potential of 28.95%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 22.95%. Given that LeMaitre Vascular has higher upside potential than Insulet, analysts believe LeMaitre Vascular is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    LMAT
    LeMaitre Vascular
    3 6 0
    PODD
    Insulet
    14 4 0
  • Is LMAT or PODD More Risky?

    LeMaitre Vascular has a beta of 0.888, which suggesting that the stock is 11.173% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

  • Which is a Better Dividend Stock LMAT or PODD?

    LeMaitre Vascular has a quarterly dividend of $0.20 per share corresponding to a yield of 0.83%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 32.65% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LMAT or PODD?

    LeMaitre Vascular quarterly revenues are $55.7M, which are smaller than Insulet quarterly revenues of $597.5M. LeMaitre Vascular's net income of $11.2M is lower than Insulet's net income of $100.7M. Notably, LeMaitre Vascular's price-to-earnings ratio is 42.22x while Insulet's PE ratio is 44.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 8.48x versus 9.11x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LMAT
    LeMaitre Vascular
    8.48x 42.22x $55.7M $11.2M
    PODD
    Insulet
    9.11x 44.12x $597.5M $100.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock